U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 5 of 5 results

Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Alisertib (MLN8237) is an orally available selective aurora A kinase inhibitor developed by Takeda. Alisertib inhibited AAK over ABK with a selectivity of more than 200-fold in cells and produced a dose-dependent decrease in bipolar and aligned chrom...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)



Lumiracoxib is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug. On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due t...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ABSOLUTE)



Peruvoside, main component of neriperside, a tevetoside extracted from Thevitia neriifolia Juss, cardiac glycoside, is used for the treatment of heart failure. It is Na+, K(+)-ATPase inhibitor. Peruvoside also demonstrates anti-cancer activities. Per...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Alisertib (MLN8237) is an orally available selective aurora A kinase inhibitor developed by Takeda. Alisertib inhibited AAK over ABK with a selectivity of more than 200-fold in cells and produced a dose-dependent decrease in bipolar and aligned chrom...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Alisertib (MLN8237) is an orally available selective aurora A kinase inhibitor developed by Takeda. Alisertib inhibited AAK over ABK with a selectivity of more than 200-fold in cells and produced a dose-dependent decrease in bipolar and aligned chrom...